(Q33889873)

29 July 2017

1 reference

title

Is òne cycle every three or four weeks' obsolete? A critical review of dose-dense chemotherapy in solid neoplasms (English)

1 reference

29 July 2017

1 reference

K Fizazi

1

1 reference

PubMed ID

10761747

29 July 2017

L Zelek

series ordinal

2

1 reference

29 July 2017

1 February 2000

1 reference

29 July 2017

1 reference

29 July 2017

11

1 reference

29 July 2017

133-149

1 reference

29 July 2017

2

1 reference

High-dose chemotherapy with autologous stem cell support in patients with breast cancer

29 July 2017

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Do authors of review articles use systematic methods to identify, assess and synthesize information?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

The medical review article: state of the science

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Multiple-drug weekly chemotherapy versus standard combination regimen in small-cell lung cancer: a phase III randomized study conducted by the European Lung Cancer Working Party

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Randomized trial comparing weekly versus 3-week chemotherapy in small-cell lung cancer: a Cancer Research Campaign trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer. The Japan Clinical Oncology Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Can cytotoxic dose-intensity be increased by using granulocyte colony-stimulating factor? A randomized controlled trial of lenograstim in small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Received dose-intensity: a randomized trial of weekly chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: a multicenter randomized phase III study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Intensive weekly chemotherapy for the treatment of extensive-stage small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Enhanced myelotoxicity due to granulocyte colony-stimulating factor administration until 48 hours before the next chemotherapy course in patients with small-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Dose-intensive weekly chemotherapy for treatment of relapsed small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Treatment of small-cell lung cancer with an alternating chemotherapy regimen given at weekly intervals: a Southwest Oncology Group pilot study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

High dose-intensity chemotherapy, with accelerated cyclophosphamide-doxorubicin-etoposide and granulocyte-macrophage colony stimulating factor, in the treatment of small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of C

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

BOP/VIP - A new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Vincristine, cisplatin, and bleomycin with surgery in the management of advanced metastatic nonseminomatous testis tumors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Accelerated chemotherapy for poor prognosis germ cell tumours

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Cisplatin, etoposide, ifosfamide, vincristine and bleomycin combination chemotherapy for far advanced testicular carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Intensive chemotherapy in poor-prognosis nonseminomatous germ cell tumors of the testis

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Comparison of criteria for assigning germ cell tumor patients to "good risk" and "poor risk" studies

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Rapidly recycled, intensive alternating chemotherapy in heavily pretreated progressive nonseminomatous germ cell tumors a feasibility study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Dose intensification of cisplatin chemotherapy through biweekly administration

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Treatment of high-risk gestational trophoblastic disease with chemotherapy combinations containing cisplatin and etoposide

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Gestational trophoblastic disease

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Feasibility of dose-intensive continuous 5-fluorouracil, doxorubicin, and cyclophosphamide as adjuvant therapy for breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative breast cancer: an Intergroup study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Intensive outpatient adjuvant therapy for breast cancer: results of dose escalation and quality of life

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

The bigger the better? ... or what we know and what we still need to learn about anthracycline dose per course, dose density and cumulative dose in the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Weekly adriamycin versus VAC in advanced breast cancer. A randomized trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Doxorubicin in advanced breast cancer: influence of schedule on response, survival and quality of life

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administration

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Granulocyte-macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Comparative study of dose escalation versus interval reduction to obtain dose-intensification of epirubicin and cyclophosphamide with granulocyte colony-stimulating factor in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

A randomized study of epirubicin monotherapy every four or every two weeks in advanced breast cancer. A Hellenic Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Accelerated chemotherapy with high-dose epirubicin and cyclophosphamide plus r-met-HUG-CSF in locally advanced and metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

An EORTC pilot study of filgrastim (recombinant human granulocyte colony stimulating factor) as support to a high dose-intensive epiadriamycin-cyclophosphamide regimen in chemotherapy-naive patients with locally advanced or metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Dose intensity analysis in advanced ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecology Cancer Trials Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

A randomised dose intensity study in ovarian carcinoma comparing chemotherapy given at four week intervals for six cycles with half dose chemotherapy given for twelve cycles

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

A randomised trial investigating the dose intensity of primary chemotherapy in patients with ovarian carcinoma: A comparison of chemotherapy given every four weeks with the same chemotherapy given at three week intervals

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

A phase I study of bi-weekly paclitaxel/cisplatin as initial therapy for advanced ovarian cancer. A study of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

A study of ovarian cancer patients treated with dose-intensive chemotherapy supported with peripheral blood progenitor cells mobilised by filgrastim and cyclophosphamide

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

The Ewing Family of Tumors -- A Subgroup of Small-Round-Cell Tumors Defined by Specific Chimeric Transcripts

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Oxaliplatin: a review of preclinical and clinical studies.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Grou

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Schedule-intensified M-VAC chemotherapy for advanced urothelial cancer with recombinant human granulocyte colony stimulating factor (rhG-CSF).

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Phase II study of weekly high-dose cisplatin for six cycles in patients with locally advanced squamous cell carcinoma of the head and neck

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Phase II study of weekly 4'-epidoxorubicin in patients with metastatic adenocarcinoma of the cervix: an EORTC Gynaecological Cancer Cooperative Group study.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Accelerated epirubicin-ifosfamide-dacarbazine regimen in patients with adult soft tissue sarcomas

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Weekly high-dose cisplatin in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Higher doses of alpha-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

What is the effect of adjusting epirubicin doses for body surface area?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008344014518

7 January 2021

Identifiers

DOI

10.1023/A:1008344014518

1 reference

29 July 2017

1 reference

PubMed ID

10761747